The Preventive and Therapeutic Efficacy of Finasteride and Dutasteride in TRAMP Mice

    April 2013 in “ The FASEB Journal ”
    Alexander B. Opoku‐Acheampong, Dave Unis, Amanda P. Beck, Jamie Henningson, Brian Lindshield
    TLDR Dutasteride showed some prevention of prostate issues but also had limitations, especially with high-grade tumors.
    The study investigated the preventive and therapeutic efficacy of finasteride and dutasteride in TRAMP mice, focusing on prostate cancer development. Finasteride, which inhibits only 5αR2, was hypothesized to be less effective than dutasteride, which inhibits both 5αR1 and 5αR2. Mice were divided into control and drug diet groups, with treatments starting at 6 and 12 weeks of age and ending at 20 weeks. The study found that pre-dutasteride treatment reduced final body weights and genitourinary tract weights, while both pre- and post-dutasteride treatments decreased high-grade prostatic intraepithelial neoplasia (PIN) incidence. However, there was an increased incidence of poorly differentiated cancer in the dorsal lobe for pre-dutasteride and both finasteride groups. These findings showed some similarities with previous clinical trial results.
    Discuss this study in the Community →

    Related Community Posts Join

    6 / 1000+ results
      FCE 28260: A Forgotten 5α-Reductase Inhibitor

      community FCE 28260: A Forgotten 5α-Reductase Inhibitor

      in Research  330 upvotes 1 year ago
      FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.

      community NW5 at 19. How many grafts do I need?

      in Transplants  140 upvotes 2 years ago
      A 19-year-old with rapid hair loss since 16 is considering a hair transplant but refuses to take finasteride or any 5α-Reductase inhibitors. They are currently using minoxidil, tretinoin, and microneedling with a Derminator 2, and only want hair until age 27.

      community New & Improved Hair Growth Stack for Maximum Results

      in Treatment  4 upvotes 1 year ago
      A user shared a hair growth stack using minoxidil sulfate, valproic acid, bimatoprost, blue copper peptide, and other ingredients, emphasizing a gel-based formula for better skin tolerance. Another user suggested adding a 5-alpha-reductase inhibitor like finasteride or dutasteride for more effective long-term results.

    Related Research

    3 / 3 results